Immunosys

Founded in 2016 and based in London/Manchester, Immunosys is a specialized scientific consulting firm and partial owner of a preclinical CRO, focusing on immunology and infectious disease. Its core business model is providing high-level consulting services and laboratory work to support drug discovery, particularly in developing novel in vitro human cellular systems for assessing immunological risk. The company has demonstrated capability through completed grant-funded R&D projects, positioning itself as an expert partner in human in vitro biology for biopharma clients.

Expertise in developing novel preclinical in vitro human cellular models for immunological risk assessment, particularly for drug-induced tissue damage. Core platform is methodological IP and scientific consulting in immunology and protein biology.

Immunosys competes in a crowded market of preclinical CROs and scientific consultants. It differentiates through a sharp focus on immunology and its novel in vitro modeling expertise. However, it faces competition from global full-service CROs (e.g., Charles River, Labcorp), specialized immunology CROs, and numerous independent consultants, requiring it to continually demonstrate superior scientific value.